HAEM5:B-lymphoblastic leukaemia/lymphoma with BCR::ABL1-like features: Difference between revisions
No edit summary |
No edit summary |
||
| Line 5: | Line 5: | ||
==Primary Author(s)*== | ==Primary Author(s)*== | ||
Mark G. Evans, MD, Caris Life Sciences | Mark G. Evans, MD, Caris Life Sciences | ||
Sumire Kitahara, MD, Cedars-Sinai, Los Angeles | |||
==WHO Classification of Disease== | ==WHO Classification of Disease== | ||
| Line 740: | Line 742: | ||
==References== | ==References== | ||
<references /> | |||
==Notes== | ==Notes== | ||
| Line 747: | Line 749: | ||
Prior Author(s): Fabiola Quintero-Rivera, MD | Prior Author(s): Fabiola Quintero-Rivera, MD | ||
<nowiki>*</nowiki>''Citation of this Page'': “B-lymphoblastic leukaemia/lymphoma with BCR::ABL1-like features”. Compendium of Cancer Genome Aberrations (CCGA), Cancer Genomics Consortium (CGC), updated {{REVISIONMONTH}}/{{REVISIONDAY}}/{{REVISIONYEAR}}, <nowiki>https://ccga.io/index.php/HAEM5:B-lymphoblastic_leukaemia/lymphoma_with_BCR::ABL1-like_features</nowiki>. | <nowiki>*</nowiki>''Citation of this Page'': Evans MG, Kitahara S. “B-lymphoblastic leukaemia/lymphoma with BCR::ABL1-like features”. Compendium of Cancer Genome Aberrations (CCGA), Cancer Genomics Consortium (CGC), updated {{REVISIONMONTH}}/{{REVISIONDAY}}/{{REVISIONYEAR}}, <nowiki>https://ccga.io/index.php/HAEM5:B-lymphoblastic_leukaemia/lymphoma_with_BCR::ABL1-like_features</nowiki>. | ||
[[Category:HAEM5]] | [[Category:HAEM5]] | ||
[[Category:DISEASE]] | [[Category:DISEASE]] | ||
[[Category:Diseases B]] | [[Category:Diseases B]] | ||